FDA-Subject by formulation interaction (Switchability) [Regulatives / Guidelines]

posted by jag009  – NJ, 2018-03-28 23:33 (2182 d 14:17 ago) – Posting: # 18607
Views: 2,760

❝ Now, as we are doing a fully replicate study as suggested by OGD recommendation on methyl­phenidate, can we use RSABE approach in case if we get ISCV-reference > 30% for any one of the PK parameter Cmax or partial AUCs, instead of using 90% CI calculation to prove the bio­equivalence?


Yes. Reason is that it is possible for one of those PK parameters to show ISCV > 30%.
As an added bonus, even if a BE guidance states that crossover studies are required but you have data to support that the drug of interest is HVD (ISCV>30%, provided that the high ISCV is not because your formulation is crap) then you can run the studies as replicates. I have done 2 projects in the past already.

P.S. You woke me up from my hibernation Helmut... :-)

John

Complete thread:

UA Flag
Activity
 Admin contact
22,940 posts in 4,812 threads, 1,640 registered users;
47 visitors (1 registered, 46 guests [including 6 identified bots]).
Forum time: 12:50 CET (Europe/Vienna)

Those people who think they know everything
are a great annoyance to those of us who do.    Isaac Asimov

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5